Mankind Pharma is currently trading at Rs. 1895.00, up by 7.20 points or 0.38% from its previous closing of Rs. 1887.80 on the BSE.
The scrip opened at Rs. 1925.60 and has touched a high and low of Rs. 1925.60 and Rs. 1886.00 respectively. So far 3933 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 2039.95 on 21-Nov-2023 and a 52 week low of Rs. 1240.75 on 22-May-2023.
Last one week high and low of the scrip stood at Rs. 2037.75 and Rs. 1820.15 respectively. The current market cap of the company is Rs. 76432.27 crore.
The promoters holding in the company stood at 76.50%, while Institutions and Non-Institutions held 8.74% and 14.76% respectively.
Mankind Pharma has made investment of British pound sterling 999,900 in Actimed Therapeutics (Actimed) on December 15, 2023. It is a strategic investment in the field of treatment of cancer cachexia, amyotrophic lateral sclerosis and other muscle wasting disorders. Post this investment the aggregate shareholding of the Company in Actimed will be around 10.19%.
Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: